Ganglioside complexes as targets for antibodies in Miller Fisher syndrome
- Correspondence to: H J Willison Department of Neurology, Division of Clinical Neurosciences, University of Glasgow, Southern General Hospital, Glasgow G51 4TF, Scotland; h.j.willison{at}clinmed.gla.ac.uk
- Published Online First 5 June 2006
The specificity of Miller Fisher syndrome sera for ganglioside complexes may influence its pathogenesis
In the early 1990s, Kusunoki’s group1,2 showed, in two seminal papers, that antibodies directed against the ganglioside GQ1b were present in the acute-phase sera of patients with Miller Fisher syndrome (MFS). Since then, numerous studies have been published which show that anti-GQ1b antibodies and closely related anti-GT1a antibodies have a central role in MFS pathogenesis.3 In the latest paper from Kusunoki’s group by Kaida et al4(see page 1043), another fundamental issue surrounding anti-GQ1b antibodies has been uncovered, which confounds several issues and adds an intriguing layer of complexity to this highly …
